Pfenex

Headquartered in San Diego, California, PfÄ“nex Inc. is a leading biotechnology company focused on recombinant protein expression for a broad range of applications including therapeutic proteins, vaccines, research, reagents and biosimilars. The Company's core technology, PfÄ“nex Expression Technologyâ„¢, is a cutting edge protein expression platform that utilizes the BSL-1 microorganism Pseudomonas fluorescens. PfÄ“nex Expression Technologyâ„¢ combines an extensive toolbox of expression components with a robotically enabled high throughput parallel strain screening technology, delivering unprecedented speed and success in identifying protein production strains expressing high titers of soluble active protein.

Investors need to pay close attention to Pfenex (PFNX) stock based on the movements in the options market lately.

Implied Volatility Surging for Pfenex (PFNX) Stock Options

New Exclusive Commercialization Agreements in South Korea, Canada, and Israel

Pfenex Provides Update for PF708 Outside the United States

Pfenex (PFNX) news for Monday about it getting approval for its new osteoporosis treatment has PFNX stock soaring higher.

Pfenex News: PFNX Stock Surges on Osteoporosis Treatment Approval

Pfenex earns a $2.5M milestone payment from Alvogen for U.S. approval

Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis

SAN DIEGO, Sept.  16, 2019  (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced that Eef Schimmelpennink, President and Chief Executive Officer, will be presenting at the Cantor Healthcare Conference on Thursday, October 3rd, taking place at the Intercontinental Hotel in New York City, October 2nd through 4th.

Pfenex to Present at the Cantor Healthcare Conference

SAN DIEGO, Sept.  10, 2019  (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced that Eef Schimmelpennink, President and Chief Executive Officer, and Susan Knudson, Chief Financial Officer, will be participating in one-on-one investor meetings at the Oppenheimer Fall Summit focused on specialty pharma and rare disease companies, taking place at the Parker Hotel in New York City on September 23rd - 24th.

Pfenex to Participate in the Oppenheimer Fall Summit

SAN DIEGO, Sept.  05, 2019  (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that it has earned an $11 million development milestone under its development and license agreement with Jazz Pharmaceuticals. The milestone is associated with process development activities for PF745, a recombinant crisantaspase with half-life extension technology.

Pfenex Earns $11 Million Development Milestone under its Development and License Agreement with Jazz Pharmaceuticals

SAN DIEGO, Sept.  04, 2019  (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced the appointment of Steve Kay, Ph.D., to the Pfenex Scientific Advisory Board.

Pfenex Appoints Dr. Steve Kay to Scientific Advisory Board

Pfenex's (PFNX) CEO Eef Schimmelpennink on Q2 2019 Results - Earnings Call Transcript

Pfenex (PFNX) delivered earnings and revenue surprises of 4.00% and -50.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Pfenex (PFNX) Reports Q2 Loss, Misses Revenue Estimates

Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Pfenex (PFNX) Report Negative Earnings Next Week? What You Should Know

Pfenex has been struggling lately, but the selling pressure may be coming to an end soon.

Pfenex Sees Hammer Chart Pattern: Time to Buy?

As of late, it has definitely been a great time to be an investor in Pfenex Inc. (PFNX).

Pfenex Inc. (PFNX) Shares March Higher, Can It Continue?

PFNX develops biosimilars to major drugs approaching patent expiry.

Pfenex: The First U.S. Forteo Biosim And A Host Of Other Biosims In Pipeline

Pfenex's (PFNX) CEO Eef Schimmelpennink on Q1 2019 Results - Earnings Call Transcript

Pfenex (PFNX) delivered earnings and revenue surprises of 52.00% and 84.05%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Pfenex (PFNX) Reports Q1 Loss, Tops Revenue Estimates

Pfenex (PFNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

As of late, it has definitely been a great time to be an investor in Pfenex.

Will Pfenex Continue to Surge Higher?

Pfenex (PFNX) delivered earnings and revenue surprises of 29.03% and -46.64%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Pfenex (PFNX) Reports Q4 Loss, Misses Revenue Estimates

Wall Street analysts see Pfenex reporting a loss of 35 cents per share on revenue of $4.4 million.

News for Pfenex Stock (PFNX)